In general, there is increasing evidence that the beneficial effects of GDF8 inhibition as a therapeutic strategy in muscle-wasting conditions, such as cachexia, age-related atrophy, or muscular dystrophies, need to be evaluated with care. The gene discussed is MSTN; the disease is Cachexia.